Goldman Sachs Group Inc. Has $151,000 Holdings in Actuate Therapeutics, Inc. $ACTU

Goldman Sachs Group Inc. raised its position in Actuate Therapeutics, Inc. (NASDAQ:ACTU) by 98.7% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 22,358 shares of the company’s stock after acquiring an additional 11,105 shares during the period. Goldman Sachs Group Inc. owned approximately 0.11% of Actuate Therapeutics worth $151,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in ACTU. Chicago Partners Investment Group LLC bought a new position in shares of Actuate Therapeutics in the first quarter valued at approximately $70,000. Sfmg LLC bought a new position in shares of Actuate Therapeutics in the first quarter valued at approximately $74,000. Sigma Planning Corp lifted its holdings in shares of Actuate Therapeutics by 47.3% in the first quarter. Sigma Planning Corp now owns 23,675 shares of the company’s stock valued at $160,000 after purchasing an additional 7,600 shares in the last quarter. Finally, Voss Capital LP lifted its holdings in shares of Actuate Therapeutics by 157.7% in the first quarter. Voss Capital LP now owns 142,381 shares of the company’s stock valued at $964,000 after purchasing an additional 87,135 shares in the last quarter.

Wall Street Analyst Weigh In

ACTU has been the topic of a number of recent research reports. B. Riley initiated coverage on Actuate Therapeutics in a report on Tuesday, August 26th. They issued a “buy” rating and a $20.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Actuate Therapeutics in a report on Tuesday, September 23rd. Finally, Wall Street Zen upgraded Actuate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $20.33.

Actuate Therapeutics Stock Performance

Shares of ACTU opened at $6.77 on Tuesday. The stock’s fifty day moving average price is $7.58 and its two-hundred day moving average price is $7.93. Actuate Therapeutics, Inc. has a 1 year low of $5.47 and a 1 year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.11).

Actuate Therapeutics Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.